MCID: DBT006
MIFTS: 49

Diabetic Macular Edema

Categories: Eye diseases

Aliases & Classifications for Diabetic Macular Edema

MalaCards integrated aliases for Diabetic Macular Edema:

Name: Diabetic Macular Edema 12 51 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:9191
ICD9CM 34 362.07
SNOMED-CT 64 312912001
UMLS 69 C0730285

Summaries for Diabetic Macular Edema

MalaCards based summary : Diabetic Macular Edema is related to macular retinal edema and macular degeneration, age-related, 1. An important gene associated with Diabetic Macular Edema is VEGFA (Vascular Endothelial Growth Factor A), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Dexamethasone and Pioglitazone have been mentioned in the context of this disorder. Affiliated tissues include eye, endothelial and retina, and related phenotypes are cardiovascular system and hematopoietic system

Related Diseases for Diabetic Macular Edema

Diseases related to Diabetic Macular Edema via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 116)
# Related Disease Score Top Affiliating Genes
1 macular retinal edema 31.4 ICAM1 IL6 PRKCB SERPINF1 VEGFA
2 macular degeneration, age-related, 1 30.1 CCL2 FGF2 SERPINF1 VEGFA
3 retinal vein occlusion 30.1 CCL2 IL6 SERPINF1 VEGFA
4 macular holes 30.0 CCL2 SERPINF1 VEGFA
5 ischemia 29.7 ICAM1 NOS3 VEGFA
6 microvascular complications of diabetes 5 28.8 FGF2 ICAM1 NOS3 PRKCB SERPINF1 TEK
7 microvascular complications of diabetes 1 28.7 CCL2 FGF2 ICAM1 SERPINF1 SST VEGFA
8 diabetes mellitus, noninsulin-dependent 28.2 CCL2 IL6 NOS3 SST
9 hydrops, lactic acidosis, and sideroblastic anemia 11.2
10 retinitis 10.7
11 endotheliitis 10.5
12 spinal disease 10.4 IL6 VEGFA
13 diabetic cataract 10.4 SERPINF1 VEGFA
14 poems syndrome 10.4 IL6 VEGFA
15 primary effusion lymphoma 10.4 IL6 VEGFA
16 endophthalmitis 10.4 ICAM1 VEGFA
17 pyogenic granuloma 10.3 TEK VEGFA
18 hydrocele 10.3 ICAM1 VEGFA
19 chronic eosinophilic pneumonia 10.3 ICAM1 IL6
20 capillary hemangioma 10.3 TEK VEGFA
21 denture stomatitis 10.3 CCL2 IL6
22 herpes simplex virus keratitis 10.3 CCL2 ICAM1
23 retinal vascular occlusion 10.3 CCL2 VEGFA
24 aging 10.3
25 leukostasis 10.3 ICAM1 VEGFA
26 cataract 10.3
27 hypersensitivity reaction type iii disease 10.3 ICAM1 IL6
28 stachybotrys chartarum 10.3 CCL2 IL6
29 acute proliferative glomerulonephritis 10.3 CCL2 ICAM1
30 radiation proctitis 10.3 FGF2 VEGFA
31 intussusception 10.3 IL6 TEK
32 lymphangioma 10.2 SERPINF1 VEGFA
33 laryngitis 10.2 FGF2 IL6
34 central retinal vein occlusion 10.2 IL6 SERPINF1 VEGFA
35 eales disease 10.2 IL6 SERPINF1 VEGFA
36 angiomatous meningioma 10.2 FGF2 VEGFA
37 tuberculous meningitis 10.2 CCL2 VEGFA
38 radiculopathy 10.2 CCL2 IL6
39 retinal vascular disease 10.2 ICAM1 SERPINF1 VEGFA
40 dupuytren contracture 10.2 FGF2 VEGFA
41 nodular goiter 10.2 ICAM1 IL6 VEGFA
42 polyarteritis nodosa, childhood-onset 10.2
43 vitreous detachment 10.2
44 vitreous disease 10.2 FGF2 VEGFA
45 cortical thymoma 10.2 ICAM1 SST
46 stromal keratitis 10.2 CCL2 IL6
47 critical limb ischemia 10.2 IL6 TEK VEGFA
48 carcinoid syndrome 10.1 SST VEGFA
49 idiopathic interstitial pneumonia 10.1 CCL2 ICAM1 VEGFA
50 endometriosis 10.1 CCL2 IL6 VEGFA

Graphical network of the top 20 diseases related to Diabetic Macular Edema:



Diseases related to Diabetic Macular Edema

Symptoms & Phenotypes for Diabetic Macular Edema

MGI Mouse Phenotypes related to Diabetic Macular Edema:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.03 IL6 TEK NOS3 VEGFA FGF2 PRKCB
2 hematopoietic system MP:0005397 9.97 VEGFA IL6 TEK NOS3 FGF2 PRKCB
3 homeostasis/metabolism MP:0005376 9.97 SST IL6 TEK NOS3 CASP14 FGF2
4 digestive/alimentary MP:0005381 9.88 SST IL6 NOS3 ICAM1 SERPINF1 VEGFA
5 immune system MP:0005387 9.86 SST VEGFA IL6 CCL2 NOS3 PRKCB
6 muscle MP:0005369 9.63 VEGFA IL6 TEK NOS3 FGF2 ICAM1
7 nervous system MP:0003631 9.61 IL6 TEK NOS3 VEGFA FGF2 PRKCB
8 vision/eye MP:0005391 9.17 IL6 TEK NOS3 VEGFA FGF2 ICAM1

Drugs & Therapeutics for Diabetic Macular Edema

Drugs for Diabetic Macular Edema (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 233)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 50-02-2 5743
2
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
3
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
4
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 124-94-7 31307
5
Ranibizumab Approved Phase 4,Phase 2,Phase 3,Phase 1 347396-82-1 459903
6
Nepafenac Approved, Investigational Phase 4,Phase 3,Phase 2 78281-72-8 151075
7
Bevacizumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 216974-75-3
8
Povidone-iodine Approved Phase 4,Phase 3 25655-41-8
9
Linagliptin Approved Phase 4 668270-12-0 10096344
10
Betamethasone Approved, Vet_approved Phase 4,Phase 2,Phase 3 378-44-9 9782
11
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
12
Moxifloxacin Approved, Investigational Phase 4 151096-09-2, 354812-41-2 152946
13
Menthol Approved Phase 4 2216-51-5 16666
14
Fluocinolone Acetonide Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 67-73-2 6215
15 Homatropine Approved Phase 4 87-00-3
16
Glimepiride Approved Phase 4 93479-97-1 3476
17
Verteporfin Approved, Investigational Phase 4 129497-78-5
18
Empagliflozin Approved Phase 4 864070-44-0
19
Benzocaine Approved, Investigational Phase 4,Phase 1,Phase 2 1994-09-7, 94-09-7 2337
20 tannic acid Approved, Nutraceutical Phase 4,Phase 1,Phase 2
21
Lactitol Investigational Phase 4 585-86-4 3871
22
Bromfenac Approved July 1997 Phase 4,Phase 1 91714-94-2 60726
23
2,4-thiazolidinedione Investigational Phase 4 2295-31-0
24 triamcinolone acetonide Phase 4,Phase 3,Phase 2,Phase 1
25 Dexamethasone acetate Phase 4,Phase 2,Phase 3,Phase 1 1177-87-3
26 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
27 glucocorticoids Phase 4,Phase 2,Phase 3,Phase 1
28
protease inhibitors Phase 4,Phase 2,Phase 3
29 Respiratory System Agents Phase 4,Phase 2,Phase 3,Phase 1
30 Mitogens Phase 4,Phase 3,Phase 2,Phase 1
31 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1
32 Glycoside Hydrolase Inhibitors Phase 4
33 Triamcinolone diacetate Phase 4,Phase 3,Phase 2,Phase 1
34 Triamcinolone hexacetonide Phase 4,Phase 3,Phase 2,Phase 1
35 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1
36 HIV Protease Inhibitors Phase 4,Phase 2,Phase 3
37 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1
38 Dermatologic Agents Phase 4,Phase 3,Phase 1,Phase 2
39 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
40 Hormones Phase 4,Phase 2,Phase 3,Phase 1
41 Dipeptidyl-Peptidase IV Inhibitors Phase 4
42 Angiogenesis Modulating Agents Phase 4,Phase 2,Phase 3,Phase 1
43 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1
44 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1
45 Endothelial Growth Factors Phase 4,Phase 3,Phase 2,Phase 1
46 Anti-Bacterial Agents Phase 4,Phase 3,Phase 1,Phase 2
47 Hypoglycemic Agents Phase 4
48 Pharmaceutical Solutions Phase 4,Phase 2,Phase 3,Phase 1
49 Antiemetics Phase 4,Phase 2,Phase 3,Phase 1
50 Anti-Infective Agents Phase 4,Phase 1,Phase 2

Interventional clinical trials:

(show top 50) (show all 405)

# Name Status NCT ID Phase Drugs
1 Multicenter Study to Evaluate the Efficacy of Treat and Extend Regimen of Aflibercept (EYLEA) as a Second Line Treatment for Diabetic Macular Edema Unknown status NCT02633852 Phase 4 Aflibercept
2 Retinal Ganglion Cell Function After Intravitreous Ranibizumab in Patients With Diabetic Macular Edema Unknown status NCT02055911 Phase 4 Ranibizumab
3 Combination OZURDEX® & LUCENTIS® vs. OZURDEX® Monotherapy in Incomplete-Responders With Diabetic Macular Edema Unknown status NCT02684084 Phase 4 Ozurdex;Lucentis
4 Bevacizumab and Peripheral Retinal Changes on Wide Field Angiography in Diabetic Macular Edema Unknown status NCT02096874 Phase 4 Bevacizumab
5 The Endurance 1 Trial Unknown status NCT02297204 Phase 4 aflibercept 2.0 mg
6 POSTERIOR SUB-TENON'S Avastin Unknown status NCT00567372 Phase 4 bevacizumab (Sub-tenon´s injection)
7 Effect of Dexamethasone Implant in Hard Exudate Complicated With Diabetic Macular Edema Unknown status NCT02399657 Phase 4 Intravitreal dexamethasone 0.7mg implant
8 Laser Therapy Combined With Intravitreal Aflibercept vs Intravitreal Aflibercept Monotherapy (LADAMO) Unknown status NCT02432547 Phase 4 Aflibercept
9 Comparison of the Effects of Bevacizumab Before vs After Pattern Panretinal Photocoagulation Unknown status NCT00804206 Phase 4 bevacizumab;bevacizumab
10 Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion Unknown status NCT01827722 Phase 4 Ozurdex;Ranibizumab;Combination Ozurdex with Ranibizumab PRN
11 Thiazolidinedione (TZD) on the Diabetic Retinopathy and Nephropathy Unknown status NCT01175486 Phase 4 Actos (Pioglitazone);Acarbose
12 Panretinal Photocoagulation for Proliferative Diabetic Retinopathy in a Single Session Using Low Fluence Parameters Unknown status NCT01023698 Phase 4
13 A One-year Randomized Controlled Trial Evaluating the Impact of Pioglitazone Versus Linagliptin on Bone Turnover Markers Unknown status NCT02429232 Phase 4 Pioglitazone;Linagliptin
14 Intravitreal Macugen for Ischaemic Diabetic Macular Oedema Completed NCT01175070 Phase 4 Intravitreal injection of pegaptanib sodium
15 Intraocular Anti-VEGF Compared With Intraocular Triamcinolone in Patients With Diabetic Macular Edema Completed NCT00682539 Phase 4 Bevacizumab (Avastin);Triamcinolone;Sham
16 A Pilot Study on the Effect and Safety of Iluvien® in Chronic Diabetic Macular Edema Patients Completed NCT02359526 Phase 4 IlUVIEN
17 Efficacy of Ranibizumab Therapy With Aflibercept in Patients With Diabetic Macular Edema Completed NCT02646670 Phase 4 Ranibizumab;Aflibercept;Ranibizumab and Aflibercept;Aflibercept and ranibizumab
18 Topical Nepafenac as Supplement for Diabetic Macular Edema Completed NCT02443012 Phase 4 Topical Gutt Nepafenac 0.1%
19 Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Alone Versus Ozurdex Given Every 3 Months for Treatment of Persistent Diabetic Macular Edema Completed NCT02036424 Phase 4 Ozurdex;Bevacizumab
20 Efficacy Study of Triamcinolone and Bevacizumab Intravitreal for Treatment of Diabetic Macular Edema Completed NCT00737971 Phase 4 Bevacizumab intravitreal;Triamcinolone;Triamcinolone + Bevacizumab
21 Ozurdex as Adjunct to Avastin Compared to Avastin Alone in Treatment of Patients With Diabetic Macular Edema Completed NCT01309451 Phase 4 Bevacizumab;dexamethasone intravitreal implant
22 Randomized, Double Blind Trial of Bromfenac BID (0.09%) as an Adjunct to Argon Laser Therapy in the Treatment of Diabetic Macular Edema. Completed NCT00758628 Phase 4 Bromefenac;Blink
23 Unilateral Bevacizumab for Bilateral Diabetic Macular Edema Completed NCT00496405 Phase 4 bevacizumab
24 Ozurdex for Diabetic Macular Edema Treated With Pars Plana vitrEctomy and Membrane RemovAl (OPERA Study) Completed NCT01613716 Phase 4 Ozurdex
25 Intraoperative Dexamethasone Implant Improves Outcome of Cataract Surgery With Diabetic Macular Edema Completed NCT01546402 Phase 4 Dexamethasone Drug delivery system (Ozurdex)
26 Ranibizumab "Treat and Extend" in Diabetic Macular Edma Completed NCT01297569 Phase 4 Ranibizumab
27 Ranibizumab Treatment of Diabetic Macular Oedema With Bimonthly Monitoring After a Phase of Initial Treatment Completed NCT01257815 Phase 4 Ranibizumab
28 Efficacy and Safety of Lucentis® (Ranibizumab Intravitreal Injections) in Chilean Patients With Diabetic Macular Edema. Completed NCT02140411 Phase 4 Ranibizumab Intravitreal injections
29 Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease(Preserve) Study Completed NCT01486238 Phase 4 Macugen® pegaptanib sodium
30 Long-Term Efficacy & Safety of Aflibercept IVT for the Treatment of DME in Subjects Who Completed the VISTA-DME Trial Completed NCT02299336 Phase 4 Aflibercept
31 A Non-Randomized, Open-Label, Single Center Phase 4 Study of the Effect and Safety of ILUVIEN® in Chronic Diabetic Macular Edema Patients Considered Insufficiently Responsive to Available Therapies (Laser, Anti-VEGF) With or Without Intravitreal Corticost Completed NCT02472366 Phase 4 ILUVIEN
32 Investigation of the Change of Vision-related Quality of Life in Subjects Treated With Aflibercept According to EU Label for DME. Completed NCT02581995 Phase 4 Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
33 Lucentis (Ranibizumab) in Diabetic Macular Oedema: a Treatment Evaluation Completed NCT01223612 Phase 4 Ranibizumab
34 Study of Efficacy of Ranibizumab in Different Regimens in Patients With Diabetic Macula Edema Completed NCT02366468 Phase 4 0.5 mg ranibizumab;0.5 mg ranibizumab
35 Morphological and Functional Retinal Changes Following Retinal Photocoagulation Completed NCT00682240 Phase 4
36 Comparison of VA Guided Versus OCT Guided TER Using Ranibizumab for Diabetic Macular Edema (AVOCT Study) Recruiting NCT03394573 Phase 4 Ranibizumab Injection
37 Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Diabetic Macular Edema Recruiting NCT02441907 Phase 4 aflibercept
38 Effect of Aflibercept (Eylea®) in the Management of Bevacizumab (Avastin®) Resistant Diabetic Macular Edema Recruiting NCT02924987 Phase 4 Aflibercept Injection
39 Aflibercept anD navigateD vErsus coNvensional Laser in Diabetic macUlar edeMa Recruiting NCT02554747 Phase 4
40 Influence of Diabetes Control on Treatment of Diabetic Macular Edema With Ranibizumab Recruiting NCT02665689 Phase 4 ranibizumab
41 Analysis of Cytokines in Response to Treatment of Diabetic Macular Edema With 0.3mg Lucentis Recruiting NCT03097068 Phase 4 Lucentis
42 Treat-and-extend Regimen of Aflibercept in Diabetic Macular Edema (VIBIM Study) Recruiting NCT02788877 Phase 4 aflibercept
43 Treatment of Diabetic Macular Edema With Aflibercept in Subjects Previously Treated With Ranibizumab or Bevacizumab Recruiting NCT02559180 Phase 4 aflibercept
44 IAI for Persistent DME After Treatment With Bevacizumab And Ranibizumab Recruiting NCT03340610 Phase 4 Alflibercept
45 Empagliflozin Reduces Progression of Diabetic Retinopathy in Patients With High Risk of Diabetic Macular Edema Recruiting NCT02985242 Phase 4 Empagliflozin;Glimepiride;Empagliflozin placebo;Glimepiride placebo
46 Evaluation of the Effect of Intravitreal Injections of Anti-VEGF on Macular Perfusion in Diabetic Patients Using OCTA Recruiting NCT03246152 Phase 4 Bevacizumab
47 Continuation of Previous Study to Gather More Data on Effect of Macugen on the Corneal Endothelium Recruiting NCT01573572 Phase 4 pegaptanib sodium injection
48 Cohort Study of the Clinical Course of Macular Diseases in Kagawa Recruiting NCT02321267 Phase 4 ranibizumab, aflibercept, pegaptanib, verteporphin
49 Dexamethasone Intravitreal Implant for the Treatment of Persistent Diabetic Macular Edema Active, not recruiting NCT02471651 Phase 4 Dexamethasone intravitreal implant (0.7 mg);Intravitreal anti-VEGF injection
50 Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Macular Edema in Subjects Who Completed the Three Year VISTA-DME Trial (The Endurance 2 Trial) Active, not recruiting NCT02368756 Phase 4 Aflibercept

Search NIH Clinical Center for Diabetic Macular Edema

Genetic Tests for Diabetic Macular Edema

Anatomical Context for Diabetic Macular Edema

MalaCards organs/tissues related to Diabetic Macular Edema:

38
Eye, Endothelial, Retina, Testes, Bone, Monocytes

Publications for Diabetic Macular Edema

Articles related to Diabetic Macular Edema:

(show top 50) (show all 684)
# Title Authors Year
1
One-Year Outcome of Conbercept Therapy for Diabetic Macular Edema. ( 29265939 )
2018
2
Pharmacology of Corticosteroids for Diabetic Macular Edema. ( 29297055 )
2018
3
Visual Outcomes Based on Early Response to Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema. ( 29316563 )
2018
4
Aflibercept for clinically significant diabetic macular edema: 12-month results in daily clinical practice. ( 29386883 )
2018
5
Detailed analysis of retinal morphology in patients with diabetic macular edema (DME) randomized to ranibizumab or triamcinolone treatment - reply to the letter to the editor. ( 29368041 )
2018
6
Disorganization of Inner Retina and Outer Retinal Morphology in Diabetic Macular Edema. ( 29327033 )
2018
7
An exudate detection method for diagnosis risk of diabetic macular edema in retinal images using feature-based and supervised classification. ( 29318442 )
2018
8
Intravitreal dexamethasone implants for diabetic macular edema. ( 29375995 )
2018
9
Efficiency of fenofibrate in facilitating the reduction of central macular thickness in diabetic macular edema. ( 29283132 )
2018
10
Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema: Does Flavor Matter? ( 29392302 )
2018
11
Detailed analysis of retinal morphology in patients with diabetic macular edema (DME) randomized to ranibizumab or triamcinolone treatment. ( 29353345 )
2018
12
Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial. ( 29392288 )
2018
13
Evaluation of contrast sensitivity and other visual function outcomes in diabetic macular edema patients following treatment switch to aflibercept from ranibizumab. ( 29403260 )
2018
14
Multimodal Imaging in Diabetic Macular Edema. ( 29376234 )
2018
15
Association Between Soluble CD14 in the Aqueous Humor and Hyperreflective Foci on Optical Coherence Tomography in Patients With Diabetic Macular Edema. ( 29392317 )
2018
16
Targeted Retinal Photocoagulation for Diabetic Macular Edema with Peripheral Retinal Nonperfusion: Three-Year Randomized DAVE Trial. ( 29336896 )
2018
17
Combined Phacoemulsification and Intravitreal Dexamethasone Implant (OzurdexAr) in Diabetic Patients with Coexisting Cataract and Diabetic Macular Edema. ( 28884024 )
2017
18
Evidence-Based Treatment of Diabetic Macular Edema. ( 28060586 )
2017
19
A Revised Approach for the Detection of Sight-Threatening Diabetic Macular Edema. ( 27930756 )
2017
20
CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA. ( 29280940 )
2017
21
The Distribution of Leakage on Fluorescein Angiography in Diabetic Macular Edema: A New Approach to Its Etiology. ( 28796876 )
2017
22
Optical Coherence Tomography Biomarkers as Functional Outcome Predictors in Diabetic Macular Edema Treated with Dexamethasone Implant. ( 28935399 )
2017
23
Efficacy of 0.2a88I1g/day fluocinolone acetonide implant (ILUVIEN) in eyes with diabetic macular edema and prior vitrectomy. ( 28085139 )
2017
24
Multicenter, Randomized Clinical Trial to Assess the Effectiveness of Intravitreal Injections of Bevacizumab, Triamcinolone, or Their Combination in the Treatment of Diabetic Macular Edema. ( 28902334 )
2017
25
Evaluation of the clinical effectiveness in routine practice of fluocinolone acetonide 190a88A/g intravitreal implant in people with diabetic macular edema. ( 28881149 )
2017
26
Evaluation of the clinical effectiveness of fluocinolone acetonide 190a88A/g intravitreal implant in diabetic macular edema: a comparison between study and fellow eyes. ( 28881143 )
2017
27
Re: Wells etA al.: Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial (Ophthalmology 2016;123:1351-1359). ( 27993278 )
2017
28
Comparison of 12-month therapeutic effect of conbercept and ranibizumab for diabetic macular edema: a real-life clinical practice study. ( 28841827 )
2017
29
Foveal Microstructure Analysis in Eyes with Diabetic Macular Edema Treated with Vitrectomy. ( 28808926 )
2017
30
Health-economic evaluation of fluocinolone acetonide 190a88A/g implant in people with diabetic macular edema. ( 28881146 )
2017
31
Reply to the Letter by Hall Entitled "ILUVIEN in Diabetic Macular Edema: The Choice of Second-Line Corticosteroid Should Be Left to the Clinical Judgement of the Treating Physician". ( 29268275 )
2017
32
Evolving Role of Regional Depot Corticosteroids in Management of Diabetic Macular Edema. ( 28837536 )
2017
33
Switching Anti-VEGF Drugs in the Treatment of Diabetic Macular Edema. ( 28902336 )
2017
34
Comparison of Intravitreal Bevacizumab and Intravitreal Diclofenac in the Treatment of Diabetic Macular Edema: a 6-month Follow-up. ( 29392145 )
2017
35
Switching to Aflibercept in Diabetic Macular Edema Not Responding to Ranibizumab and/or Intravitreal Dexamethasone Implant. ( 28900543 )
2017
36
Plasma Kallikrein Inhibitors for the Treatment of Retinal Vascular Permeability Associated with Diabetic Retinopathy and Diabetic Macular Edema. ( 28835783 )
2017
37
Efficacy of One-Year Treatment with Aflibercept for Diabetic Macular Edema with Practical Protocol. ( 29349082 )
2017
38
INTEGRITY OF OUTER RETINAL LAYERS AFTER RESOLUTION OF CENTRAL INVOLVED DIABETIC MACULAR EDEMA. ( 28092342 )
2017
39
Combined Intravitreal Dexamethasone Implant And Micropulse Yellow Laser For Treatment Of Anti-VEGF Resistant Diabetic Macular Edema. ( 28839510 )
2017
40
Long-Term Intravitreal Dexamethasone Treatment in Eyes with Pretreated Chronic Diabetic Macular Edema. ( 28836880 )
2017
41
Current and Emerging Treatment for Diabetic Macular Edema. ( 28885255 )
2017
42
Systemic Associations with Residual Subretinal Fluid after Ranibizumab in Diabetic Macular Edema. ( 28819567 )
2017
43
Choroidal Variations in Diabetic Macular Edema: Fluorescein Angiography and Optical Coherence Tomography. ( 28937826 )
2017
44
Association of statin use and hypertriglyceridemia with diabetic macular edema in patients with type 2 diabetes and diabetic retinopathy. ( 28061854 )
2017
45
Patterns of retinal thickness prior to and following treatment with fluocinolone acetonide 190a88A/g intravitreal implant for diabetic macular edema. ( 28881150 )
2017
46
Sustained intraocular pressure elevation in eyes treated with intravitreal injections of anti-vascular endothelial growth factor for diabetic macular edema in a real-life setting. ( 28831613 )
2017
47
Early and Long-term Responses to Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema: Analysis of Protocol I Data. ( 27644589 )
2016
48
Impact of injection therapy on retinal patients with diabetic macular edema or retinal vein occlusion. ( 27601878 )
2016
49
Adjunct Intravitreous Triamcinolone Acetonide in the Treatment of Diabetic Macular Edema with Anti-VEGF Agents. ( 27980863 )
2016
50
Treatments for Diabetic Macular Edema: Past, Present, and Future. ( 27631474 )
2016

Variations for Diabetic Macular Edema

Expression for Diabetic Macular Edema

Search GEO for disease gene expression data for Diabetic Macular Edema.

Pathways for Diabetic Macular Edema

Pathways related to Diabetic Macular Edema according to GeneCards Suite gene sharing:

(show all 43)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.86 CCL2 FGF2 ICAM1 IL6 NOS3 PRKCB
2
Show member pathways
13.48 CCL2 IL6 NOS3 PRKCB SERPINF1 TEK
3
Show member pathways
13.38 CCL2 FGF2 ICAM1 IL6 TEK VEGFA
4
Show member pathways
13.24 CCL2 FGF2 IL6 NOS3 PRKCB TEK
5
Show member pathways
13.2 CCL2 FGF2 ICAM1 IL6 TEK VEGFA
6
Show member pathways
13.15 CCL2 FGF2 IL6 PRKCB TEK
7
Show member pathways
13.12 FGF2 IL6 NOS3 PRKCB TEK VEGFA
8
Show member pathways
12.82 FGF2 IL6 NOS3 TEK VEGFA
9 12.7 FGF2 IL6 PRKCB VEGFA
10
Show member pathways
12.66 CCL2 ICAM1 IL6 PRKCB
11 12.62 FGF2 PRKCB TEK VEGFA
12
Show member pathways
12.59 FGF2 PRKCB TEK VEGFA
13
Show member pathways
12.48 CCL2 ICAM1 NOS3 PRKCB VEGFA
14
Show member pathways
12.39 CCL2 FGF2 IL6 NOS3 TEK
15
Show member pathways
12.35 FGF2 ICAM1 IL6 PRKCB VEGFA
16
Show member pathways
12.23 NOS3 PRKCB VEGFA
17 12.17 FGF2 PRKCB VEGFA
18
Show member pathways
12.15 CCL2 ICAM1 NOS3 PRKCB VEGFA
19
Show member pathways
12.09 FGF2 NOS3 PRKCB VEGFA
20 12.05 IL6 SST VEGFA
21 11.94 FGF2 IL6 VEGFA
22 11.92 CCL2 ICAM1 NOS3 VEGFA
23 11.89 CCL2 ICAM1 IL6
24
Show member pathways
11.84 IL6 NOS3 PRKCB
25 11.83 CCL2 ICAM1 IL6
26 11.78 CCL2 FGF2 ICAM1 IL6 VEGFA
27 11.65 CCL2 FGF2 NOS3 TEK
28 11.65 IL6 NOS3 PRKCB TEK VEGFA
29 11.56 CCL2 FGF2 IL6
30
Show member pathways
11.55 ICAM1 IL6 VEGFA
31 11.51 CCL2 ICAM1 IL6 TEK VEGFA
32 11.43 CCL2 ICAM1 IL6
33 11.42 CCL2 ICAM1 IL6
34 11.4 FGF2 IL6 VEGFA
35 11.24 ICAM1 IL6 PRKCB
36 11.22 CCL2 IL6 NOS3
37 11.1 CCL2 ICAM1 IL6 NOS3 PRKCB VEGFA
38 11.09 FGF2 VEGFA
39 11.07 CCL2 ICAM1
40 10.93 CCL2 VEGFA
41 10.89 CCL2 FGF2 IL6 TEK
42 10.84 CCL2 ICAM1
43 10.64 FGF2 NOS3 TEK VEGFA

GO Terms for Diabetic Macular Edema

Cellular components related to Diabetic Macular Edema according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.5 CCL2 FGF2 IL6 SERPINF1 SST TEK
2 extracellular space GO:0005615 9.17 CCL2 FGF2 ICAM1 IL6 SERPINF1 SST

Biological processes related to Diabetic Macular Edema according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.72 ICAM1 IL6 PRKCB
2 regulation of receptor activity GO:0010469 9.72 CCL2 FGF2 IL6 SST VEGFA
3 regulation of cell shape GO:0008360 9.71 CCL2 ICAM1 VEGFA
4 cellular response to lipopolysaccharide GO:0071222 9.7 CCL2 ICAM1 IL6
5 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.67 CCL2 FGF2 ICAM1 TEK
6 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.61 ICAM1 IL6 VEGFA
7 lipopolysaccharide-mediated signaling pathway GO:0031663 9.59 CCL2 NOS3
8 cellular response to dexamethasone stimulus GO:0071549 9.58 ICAM1 SERPINF1
9 negative regulation of endothelial cell apoptotic process GO:2000352 9.58 ICAM1 TEK
10 positive regulation of endothelial cell proliferation GO:0001938 9.58 FGF2 TEK VEGFA
11 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.57 FGF2 TEK
12 positive regulation of focal adhesion assembly GO:0051894 9.56 TEK VEGFA
13 response to hypoxia GO:0001666 9.56 ICAM1 PRKCB TEK VEGFA
14 positive regulation of vascular endothelial growth factor receptor signaling pathway GO:0030949 9.51 PRKCB VEGFA
15 cell migration involved in sprouting angiogenesis GO:0002042 9.49 FGF2 VEGFA
16 negative regulation of calcium ion transport GO:0051926 9.48 ICAM1 NOS3
17 response to acidic pH GO:0010447 9.46 SERPINF1 SST
18 angiogenesis GO:0001525 9.35 CCL2 FGF2 NOS3 TEK VEGFA
19 positive regulation of blood vessel endothelial cell migration GO:0043536 9.33 FGF2 NOS3 VEGFA
20 positive regulation of angiogenesis GO:0045766 9.02 FGF2 NOS3 PRKCB TEK VEGFA

Molecular functions related to Diabetic Macular Edema according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chemoattractant activity GO:0042056 9.16 FGF2 VEGFA
2 growth factor activity GO:0008083 9.13 FGF2 IL6 VEGFA
3 cytokine activity GO:0005125 8.92 CCL2 FGF2 IL6 VEGFA

Sources for Diabetic Macular Edema

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....